Form 4: Cytosorbents CEO Buys 100,000 Shares

Cytosorbents Corporation's CEO, Phillip P. Chan, purchased 100,000 shares of common stock in an open market transaction.

Summary

• Phillip P. Chan, CEO and Director of Cytosorbents Corp, acquired 100,000 shares of common stock.
• The transaction was an open market purchase executed on November 18, 2025, at a price of $0.64 per share.
• Following this transaction, Mr. Chan beneficially owns a total of 1,482,963 securities, which includes common stock and various restricted stock units (RSUs).
• The beneficial ownership includes RSUs granted on April 8, 2015 (130,000), June 7, 2016 (57,000), February 24, 2017 (18,700), and March 15, 2018 (10,300), all vesting upon a 'Change In Control' of the Company.
• It also includes 48,000 unvested RSUs from a grant of 96,000 on April 2, 2024, and 105,600 RSUs that vest in equal parts on the first and second year anniversaries of their grant date, subject to continued service.
• Additionally, Mr. Chan directly owns 1,113,363 shares of Common Stock.

Sentiment

Score: 8

Explanation: The CEO's significant open market purchase of 100,000 shares at $0.64 is a strong positive signal, indicating high confidence in the company's future and current valuation. This type of insider buying is generally viewed very favorably by investors.

Positives

• The CEO, Phillip P. Chan, made a significant open market purchase of 100,000 shares, indicating strong confidence in the company's future prospects and current valuation.
• The purchase price of $0.64 per share suggests management sees value at current levels, aligning their interests with those of shareholders.

Negatives

• No negative information is contained within this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future outlook, beyond the implicit confidence shown by the CEO's share purchase.

Industry Context

Insider buying, particularly by a CEO, is generally viewed as a positive signal within the market, suggesting that management believes the company's stock is undervalued or expects positive developments. This action by Cytosorbents' CEO could be interpreted by investors as a sign of internal confidence, potentially differentiating the company from peers where insider selling might occur.

Comparison to Industry Standards

• Insider purchases by a CEO are generally considered a strong signal of confidence, often outperforming general market sentiment.
• While specific comparable companies or projects are not detailed in this filing, a significant open market purchase by a top executive like Phillip P. Chan is typically viewed more favorably than smaller, routine purchases or sales, aligning with best practices for demonstrating alignment between management and shareholder interests.

Stakeholder Impact

• Shareholders: The CEO's purchase may instill greater confidence among existing shareholders and attract new investors, potentially leading to positive share price movement.
• Employees: A strong signal of management confidence can positively impact employee morale and alignment with company goals.

Next Steps

• This filing does not explicitly mention future actions, events, or milestones beyond the vesting schedules of the Restricted Stock Units.

Key Dates

Recommendation

The CEO's substantial open market purchase of 100,000 shares at $0.64 signals strong conviction in Cytosorbents' current valuation and future potential. Such a significant insider buy, especially from the Chief Executive Officer, is a powerful indicator that management believes the stock is undervalued and expects positive developments. This action suggests a favorable risk/reward profile for investors, warranting a 'buy' recommendation.

Keywords

Cytosorbents Corp, CTSO, Phillip P. Chan, CEO, Insider Buying, Stock Purchase, Form 4, Beneficial Ownership, Restricted Stock Units